3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
19
Lymphoma
5
Lung Neoplasms
5
Multiple Myeloma
4
Lymphoma, Large-Cell, Anaplastic
4
Neuroblastoma
3
Neoplasms
2
Hematologic Neoplasms
2
Carcinoma
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Neurofibromatosis 2
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Lobular
1
Carcinoma, Large Cell
1
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
1
Advanced Cancer
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
ALK-positive NSCLC
1
ALK or ROS1-positive NSCLC
1
Interventions
Sorafenib
52
pembrolizumab
26
Nivolumab
20
Bevacizumab
19
Radiosurgery
17
Doxorubicin
12
atezolizumab
9
Erlotinib Hydrochloride
9
lenvatinib
8
cabozantinib
7
Magnetic Resonance Spectroscopy
7
tremelimumab
6
durvalumab
6
Ramucirumab
6
Radiofrequency Ablation
6
Cisplatin
6
Sunitinib
5
tislelizumab
4
regorafenib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Everolimus
4
Capecitabine
4
nintedanib
3
fluoromisonidazole
3
carotuximab
3
bavituximab
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Hepatocellular
×
Crizotinib
×
Clear all
No trials found.